Marker Therapeutics (NASDAQ:MRKR) Shares Down 7.5% – Here’s Why

Marker Therapeutics, Inc. (NASDAQ:MRKR) shares fell 7.5% during mid-day trading on Friday . The company traded as low as $2.46 and last traded at $2.46. 48,743 shares traded hands during trading, an increase of 18% from the average session volume of 41,268 shares. The stock had previously closed at $2.66.

Analyst Upgrades and Downgrades

Separately, LADENBURG THALM/SH SH boosted their target price on shares of Marker Therapeutics from $11.00 to $19.00 and gave the stock a “buy” rating in a research report on Monday, October 21st.

Marker Therapeutics Price Performance

The business’s 50-day simple moving average is $3.38 and its two-hundred day simple moving average is $3.65.

Insider Activity at Marker Therapeutics

In related news, Director Steve Elms purchased 11,085 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The stock was acquired at an average price of $3.20 per share, for a total transaction of $35,472.00. Following the completion of the purchase, the director now owns 325,370 shares in the company, valued at approximately $1,041,184. This represents a 3.53 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Enterprise Associates 16 New acquired 554,250 shares of Marker Therapeutics stock in a transaction on Monday, December 23rd. The shares were bought at an average price of $3.20 per share, for a total transaction of $1,773,600.00. Following the completion of the purchase, the insider now directly owns 1,625,678 shares in the company, valued at $5,202,169.60. The trade was a 51.73 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 17.35% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Marker Therapeutics

An institutional investor recently bought a new position in Marker Therapeutics stock. Invst LLC bought a new position in shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm bought 20,000 shares of the company’s stock, valued at approximately $56,000. Invst LLC owned about 0.22% of Marker Therapeutics as of its most recent SEC filing. 22.39% of the stock is owned by institutional investors.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.